Symbols

Palisade Bio Plunges 11.48% Despite Positive Trial Results

Generated by AI AgentAinvest Pre-Market Radar

Thursday, Jul 24, 2025 5:51 am ET1min read

Aime Summary

- Palisade Bio's stock fell 11.48% pre-market despite positive Phase 1a trial results for its novel Crohn's disease drug PALI-2108.

- The company secured $3.9M through warrant exercises to fund R&D and operations following the milestone clinical data.

- Palisade Bio participated in a virtual investor conference to showcase its therapeutic pipeline and engage with stakeholders.

On July 24, 2025, Palisade Bio's stock experienced a significant drop of 11.48% in pre-market trading.

Palisade Bio recently reported positive Phase 1a results for PALI-2108, a first-in-class terminal ileum and colon-targeted PDE4 B/D inhibitor designed for fibrostenotic Crohn's disease. This development is a significant milestone for the company, as it demonstrates the potential efficacy of their novel therapeutic approach.

The company also announced an agreement with several accredited investors to exercise existing warrants, raising approximately $3.9 million. This capital infusion is expected to support the company's working capital and general corporate purposes, providing a financial boost to continue its research and development efforts.

Additionally, Palisade BioPALI-- participated in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference, showcasing its commitment to engaging with the investment community and highlighting its innovative pipeline.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue